Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

Summary of Treatment-Emergent Adverse Events (TEAE)

Count of the number of participants who experienced treatment emergent adverse events (TEAEs). TEAEs occurred during the time study intervention was being taken occurring on or after Day 1 and no longer than 30 days after the last dose of study medication.

Time frame: up to 12 weeks

Participant Summary of Best Response Across All Visits

Count of participants' best response within categories defined by the International Working Group (IWG): \> Complete Response (complete disappearance of detectable clinical and radiological evidence of disease), \> Complete Response Unconfirmed (unconfirmed complete disappearance), \> Partial Response (\>=50% decrease sum of the product of the greatest diameters in the six largest dominant nodes or nodal masses), \> Stable Disease (neither response nor disease progression), \> Progression (new lesion or increase by 50% of previously involved sites from nadir).

Time frame: up to 24 months

Kaplan-Meier Estimates of Progression-Free Survival

Time to event was measured from the date of randomization to the date of first progressive disease (PD) or death.

Time frame: 24 months

Kaplan-Meier Estimates for Duration of Partial Response or Better to Treatment

Count of days in which a participant experiences a Partial Response (\>=50% decrease sum of the product of the greatest diameters in the six largest dominant nodes or nodal masses) or better. Time to event was measured from the date of response to the date of progressive disease (PD) or death.